Comparison of multiple oncotype DX ® from the same patient-Reference-Cited by-同舟云学术

Comparison of multiple oncotype DX ® from the same patient

Published:2021-09-12 Issue:11 Volume:27 Page:828-831
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Marumoto Ashley D.¹,Mohan Srivarshini C.¹,Angarita Stephanie A.K.¹,Srour Marissa K.¹,Norton Vicky E.¹,Dadmanesh Farnaz²,Giuliano Armando E.¹

Affiliation:

1. Cedars‐Sinai Medical Center Department of Surgery Los Angeles CA USA

2. Cedars‐Sinai Medical Center Department of Pathology and Laboratory Medicine Los Angeles CA USA

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.14288

Reference20 articles.

1. Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

2. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

3. Abstract GS3‐00: first results from a phase iii randomized clinical trial of standard adjuvant endocrine therapy (ET) +/‐ chemotherapy (CT) in patients (pts) with 1‐3 positive nodes, hormone receptor‐positive (HR+) and HER2‐negative (HER2‐) breast cancer (BC) with recurrence score (RS) <25: SWOG S1007 (RxPonder);Kalinsky K;Cancer Res,2021

4. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

5. Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study